ACADIA Pharmaceuticals (ACAD) – Investment Analysts’ Recent Ratings Changes

ACADIA Pharmaceuticals (NASDAQ: ACAD) recently received a number of ratings updates from brokerages and research firms:

• 10/8/2026 – ACADIA Pharmaceuticals had its price target lowered by Royal Bank Of Canada from $37.00 to $36.00. They now have an “outperform” rating on the stock.
• 10/3/2026 – ACADIA Pharmaceuticals was downgraded by Wall Street Zen from “buy” to “hold”.
• 9/28/2026 – ACADIA Pharmaceuticals was given a new $33.00 price target by William Blair.
• 9/25/2026 – ACADIA Pharmaceuticals had its price target lowered by Deutsche Bank Aktiengesellschaft from $38.00 to $31.00. They now have a “buy” rating on the stock.
• 9/25/2026 – ACADIA Pharmaceuticals had its price target lowered by Needham & Company LLC from $41.00 to $35.00. They now have a “buy” rating on the stock.
• 9/25/2026 – ACADIA Pharmaceuticals had its “buy” rating reaffirmed by Citigroup Inc.. They now have a $33.00 price target on the stock, down from $40.00.
• 9/25/2026 – ACADIA Pharmaceuticals had its price target lowered by HC Wainwright from $37.00 to $33.00. They now have a “buy” rating on the stock.
• 9/25/2026 – ACADIA Pharmaceuticals had its price target lowered by Citizens Jmp from $36.00 to $33.00. They now have a “market outperform” rating on the stock.
• 9/24/2026 – ACADIA Pharmaceuticals had its “buy” rating reaffirmed by TD Cowen.
• 9/24/2026 – ACADIA Pharmaceuticals had its price target lowered by BMO Capital Markets from $36.00 to $34.00. They now have an “outperform” rating on the stock.
• 9/24/2026 – ACADIA Pharmaceuticals had its price target lowered by Citigroup Inc. from $40.00 to $33.00. They now have a “buy” rating on the stock.
• 9/24/2026 – ACADIA Pharmaceuticals had its “buy” rating reaffirmed by Needham & Company LLC. They now have a $41.00 price target on the stock.
• 9/23/2026 – ACADIA Pharmaceuticals had its “market perform” rating reaffirmed by Oppenheimer Holdings, Inc..
• 8/25/2026 – ACADIA Pharmaceuticals had its price target raised by Deutsche Bank Aktiengesellschaft from $37.00 to $38.00. They now have a “buy” rating on the stock.
• 8/25/2026 – ACADIA Pharmaceuticals had its price target raised by Morgan Stanley from $27.00 to $28.00. They now have an “equal weight” rating on the stock.
• 8/25/2026 – ACADIA Pharmaceuticals had its price target raised by Citigroup Inc. from $39.00 to $40.00. They now have a “buy” rating on the stock.
• 8/17/2026 – ACADIA Pharmaceuticals had its price target raised by UBS Group AG from $45.00 to $49.00. They now have a “buy” rating on the stock.
• 8/12/2026 – ACADIA Pharmaceuticals was upgraded by Weiss Ratings from “hold (c)” to “hold (c+)”.
• 8/12/2026 – ACADIA Pharmaceuticals had its price target raised by Needham & Company LLC from $38.00 to $41.00. They now have a “buy” rating on the stock.
• 8/10/2026 – ACADIA Pharmaceuticals was given a new $27.00 price target by Morgan Stanley.
• 8/10/2026 – ACADIA Pharmaceuticals had its price target raised by Citigroup Inc. from $35.00 to $39.00. They now have a “buy” rating on the stock.

Insider Activity

In other ACADIA Pharmaceuticals news, EVP Elizabeth Thompson sold 16,558 shares of ACADIA Pharmaceuticals stock in a transaction dated Thursday, July 30th. The shares were sold at an average price of $26.13, for a total value of $432,660.54. Following the sale, the executive vice president owned 18,994 shares of the company’s stock, valued at approximately $496,313.22. The trade was a 46.57% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, EVP Mark Schneyer sold 14,292 shares of the business’s stock in a transaction dated Thursday, August 6th. The shares were sold at an average price of $29.22, for a total transaction of $417,612.24. Following the completion of the transaction, the executive vice president owned 67,828 shares in the company, valued at approximately $1,981,934.16. The trade was a 17.40% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 36,699 shares of company stock worth $1,019,894. Insiders own 26.20% of the company’s stock.

ACADIA Pharmaceuticals Inc is a biopharmaceutical company focused on developing and commercializing medicines for central nervous system disorders and rare diseases. The company is headquartered in San Diego, California, and serves patients and healthcare providers primarily in the United States.

ACADIA’s commercial products include NUPLAZID (pimavanserin), an atypical antipsychotic approved in the United States for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis.